Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2YNMI)

Drug Name

MK-1654 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Respiratory syncytial virus infection	1C80	Phase 2/3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Respiratory syncytial virus protein F (RSV F)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lasofoxifene	DMHA18P	Osteoporosis	FB83.0	Approved	[3]
Palivizumab	DMQM9S0	Respiratory syncytial virus infection	1C80	Approved	[4]
SAR438584	DMDMAE4	Respiratory syncytial virus infection	1C80	Phase 3	[5]
Motavizumab	DMB24H7	Respiratory syncytial virus infection	1C80	Phase 3	[6]
GS-5806	DMDAHL6	Respiratory syncytial virus infection	1C80	Phase 2	[7]
RV521	DMSW5XJ	Respiratory syncytial virus infection	1C80	Phase 2	[8]
JNJ-53718678	DMJ1FXL	Respiratory syncytial virus infection	1C80	Phase 2	[9]
MEDI-557	DM6ADMG	Respiratory syncytial virus infection	1C80	Phase 1	[6]
TMC-353121	DMDSJO8	Respiratory syncytial virus infection	1C80	Preclinical	[3]
CL-387626	DMA4DNX	Virus infection	1A24-1D9Z	Terminated	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Respiratory syncytial virus protein F (RSV F)	TT57ID8	FUS_HRSVA	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04767373) Efficacy and Safety of MK-1654 in Infants (MK-1654-004). U.S. National Institutes of Health.
2	A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153.
3	Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470)
6	Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
7	Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43.
8	Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676.
9	Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756.
10	Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses. 2013 January; 5(1): 211-225.